CEU Statement: Response to recommendations from the Pharmacovigilance Risk Assessment Committee (PRAC) in relation to prescribing of CHC (October 2013)


Published on: 1 October 2013

File size: 98kb PDF

File type: Clinical Statements

Author: FSRH Clinical Effectiveness Unit

Following concerns in France about the risk of thromboembolism associated with the constituents of different combined hormonal contraceptives, the European Medicines Agency (EMA) started a review of the benefits and risks of the socalled third and fourth generation (newer) combined hormonal contraceptives (CHCs) in February of this year.

Your download should start automatically. If not download directly.